Uncertainty in estimates of HIV prevalence derived by backcalculation.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Uncertainty in estimates of HIV prevalence derived by backcalculation.

Ann Epidemiol. 1990 Dec;1(2):105-15. Unique Identifier : AIDSLINE MED/94093737
Rosenberg PS; Gail MH; Epidemiologic Methods Section, National Cancer Institute,; Rockville, MD.

Abstract: The incidence of consistently defined acquired immunodeficiency syndrome (AIDS) among adults in the United States was used to backcalculate the prevalence of human immunodeficiency virus (HIV) as of January 1, 1985, and July 1, 1987. The sensitivity of estimates to random and systematic sources of uncertainty was assessed. Using a standard incubation distribution with a 10-year median time-to-AIDS, we estimated that 544,000 persons were infected as of January 1, 1985, and that 992,000 persons were infected as of July 1, 1987. Variation from model selection and fitting was only 2% and 5%, respectively. Perturbations of the AIDS incidence counts to reflect plausible reporting biases reduced prevalence estimates by as much as 9.6% and 16.0%, respectively. Uncertainty about the incubation distribution had an even greater impact. A plausible range of prevalence estimates was calculated using alternative Fast and Slow incubation distributions. The plausible range varied from 415,000 to 760,000 persons in 1985 and from 737,000 to 1.4 million persons in July 1987. Inclusion of AIDS incidence counts beyond mid-1987 can lead to serious underestimates of prevalence, because use of zidovudine and other therapies beginning in mid-1987 has lengthened the incubation distribution in many severely immunodepressed persons without AIDS.

Keywords: Acquired Immunodeficiency Syndrome/DRUG THERAPY/*EPIDEMIOLOGY Adult Human HIV Seroprevalence/*TRENDS Male Models, Statistical United States Zidovudine/THERAPEUTIC USE JOURNAL ARTICLE
940430
M9440910

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .